Search - tctmd.com

Displaying 161 - 180 of 898

Sort: Relevancy | Date

News Daily News

HFSA Stats 2024 a ‘Call to Action’ Against Rising Tide of HF

L.A. McKeown

October 01, 2024

News Daily News

CVD Risk Twofold Higher in Patients With Cancer: ASPREE

Michael O'Riordan

September 27, 2024

News Daily News

Lingering Gaps in CVD Care for Women Spotlighted in British Consensus Statement

Todd Neale

September 26, 2024

News Daily News

New Guidelines for CV Care in Patients Undergoing Noncardiac Surgery

Michael O'Riordan

September 24, 2024

News Daily News

Yes, Clinical Inertia IS the Leading Cause of GDMT Underuse in HFrEF

Todd Neale

September 20, 2024

News Conference News ESC 2024

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

Michael O'Riordan

September 17, 2024

News Conference News ESC 2024

MitraClip vs Surgery for Severe FMR? MATTERHORN Claims Noninferiority

Shelley Wood

September 01, 2024

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

Presentation ESC 2024

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Presenter: Gi-Byoung Nam

September 01, 2024

Presentation ESC 2024

Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART Pooled Analysis of Cardiovascular, Kidney, and Mortality Outcomes

Presenter: Muthiah Vaduganathan

September 01, 2024

News Conference News ESC 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

Todd Neale

September 01, 2024

News Conference News ESC 2024

RESHAPE-HF2 Is a Win for MitraClip in FMR—Not Everyone’s On Board

Shelley Wood

August 31, 2024

News Conference News ESC 2024

ABYSS: Safety Signal Seen When Beta-blockers Stopped in Post-MI Patients

Michael O'Riordan

August 30, 2024

News Conference News ESC 2024

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

L.A. McKeown

August 30, 2024

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

News Daily News

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

Yael L. Maxwell

August 15, 2024

News Daily News

Scoring System Puts Focus on Medical Therapy Optimization in HFrEF

L.A. McKeown

August 13, 2024

News Daily News

Acute HF Patients Live Longer When Seen by Specialists

Michael O'Riordan

August 09, 2024

News Daily News

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

L.A. McKeown

August 05, 2024

News Daily News

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

Michael O'Riordan

July 26, 2024

Advertisement

HFSA Stats 2024 a ‘Call to Action’ Against Rising Tide of HF

CVD Risk Twofold Higher in Patients With Cancer: ASPREE

Lingering Gaps in CVD Care for Women Spotlighted in British Consensus Statement

New Guidelines for CV Care in Patients Undergoing Noncardiac Surgery

Yes, Clinical Inertia IS the Leading Cause of GDMT Underuse in HFrEF

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

MitraClip vs Surgery for Severe FMR? MATTERHORN Claims Noninferiority

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART Pooled Analysis of Cardiovascular, Kidney, and Mortality Outcomes

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

RESHAPE-HF2 Is a Win for MitraClip in FMR—Not Everyone’s On Board

ABYSS: Safety Signal Seen When Beta-blockers Stopped in Post-MI Patients

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

Scoring System Puts Focus on Medical Therapy Optimization in HFrEF

Acute HF Patients Live Longer When Seen by Specialists

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content